{"id":6152,"date":"2021-01-02T15:09:51","date_gmt":"2021-01-02T15:09:51","guid":{"rendered":"https:\/\/zeepedia.com\/?p=6152"},"modified":"2021-06-29T07:26:12","modified_gmt":"2021-06-29T07:26:12","slug":"blincyto","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/blincyto\/","title":{"rendered":"Blincyto &#8211; Blinatumomab uses, dose and side effects"},"content":{"rendered":"\n<p>\n\n38.5 micrograms&nbsp;concentrate for concentrate and solution for&nbsp;infusion&nbsp;,&nbsp;blinatumomab&nbsp;solution<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. What BLINCYTO is and what it is used for<\/h2>\n\n\n\n<p>The active substance in BLINCYTO is blinatumomab.&nbsp;It belongs to a group of drugs called cytostatic \/ cytotoxic drugs that target cancer cells.<br><\/p>\n\n\n\n<p>BLINCYTO is used to treat adults with&nbsp;acute&nbsp;lymphocytic&nbsp;leukemia&nbsp;.&nbsp;Acutelymphocytic&nbsp;leukemia&nbsp;is a cancer of the blood in which a special type of&nbsp;white blood cell&nbsp;called &#8220;B lymphocytes&#8221; multiplies uncontrollably.&nbsp;This drug works by enabling the immune system to attack and destroy these blood cancer cells.&nbsp;BLINCYTO is used when&nbsp;acute&nbsp;lymphocytic&nbsp;leukemia&nbsp;has recurred or has not responded to previous treatment (called&nbsp;recurrent&nbsp;or refractory&nbsp;acute&nbsp;lymphocytic&nbsp;leukemia&nbsp;).<br><\/p>\n\n\n\n<p>It is also used for patients with&nbsp;acute&nbsp;lymphocytic&nbsp;leukemia&nbsp;who still have a small number of cancer cells left after previous treatment (called MRD (minimal residual disease), minimal residual disease).<br><\/p>\n\n\n\n<p>BLINCYTO is used to treat children (\u2265 1 year), adolescents and young adults with&nbsp;acute&nbsp;lymphocytic&nbsp;leukemia&nbsp;(ALL) when previous treatments have not worked or have stopped working.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">2. What you need to know before using BLINCYTO<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use BLINCYTO<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>if you are allergic to blinatumomab or any of the other ingredients of this medicine (listed in section 6).<\/li><li>if you are breast-feeding.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and cautions<\/h2>\n\n\n\n<p><strong>Talk to your doctor, pharmacist or nurse before using BLINCYTO<\/strong>&nbsp;if any of the following apply to you.&nbsp;BLINCYTO may not be suitable for you:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>if you have ever had neurological problems, such as&nbsp;tremors&nbsp;, sensory disturbances, seizures, memory loss, confusion, disorientation, balance difficulties or speech difficulties.&nbsp;If you still have active neurological problems or conditions, tell your doctor.&nbsp;If the leukemia has spread to the brain and \/ or spinal cord, your doctor may need to treat this before you can start treatment with BLINCYTO.&nbsp;Your doctor will examine your nervous system and perform tests before deciding whether or not to get BLINCYTO.&nbsp;Your doctor may need to give you special care during treatment with BLINCYTO.<\/li><li>if you have an active&nbsp;infection&nbsp;.<\/li><li>if you have previously had an infusion reaction after receiving BLINCYTO.&nbsp;Symptoms may include wheezing, shortness of breath, swelling of the face, difficulty breathing, low or high&nbsp;blood pressure&nbsp;.<\/li><li>if you think you may soon need some vaccination, even those you may need when traveling abroad.&nbsp;Some vaccines must not be given within two weeks before, at the same time as or during the months following treatment with BLINCYTO.&nbsp;Your doctor will decide if you should be vaccinated.<\/li><\/ul>\n\n\n\n<p><strong>Tell a doctor, pharmacist, or nurse immediately<\/strong>&nbsp;about you<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>suffer from any of the following reactions while you are receiving BLINCYTO, as they may need to be treated and the&nbsp;dose&nbsp;adjusted:<\/li><li>if you have seizures, speech difficulties or slurred speech, confusion and disorientation or balance difficulties.<\/li><li>If you experience chills or chills, or feel hot, take the temperature and check if you have a fever, as these symptoms may mean that you have an&nbsp;infection&nbsp;.<\/li><li>if you experience any type of reaction during&nbsp;infusion&nbsp;, which may include dizziness, fainting, nausea, swelling of the face, difficulty breathing, wheezing or rash.<\/li><li>if you suffer from severe and persistent stomach pain, with or without nausea and vomiting, as this may be a symptom of a serious and potentially fatal condition called&nbsp;pancreatitis&nbsp;(&nbsp;inflammation&nbsp;of the pancreas).<\/li><\/ul>\n\n\n\n<p>Your doctor or nurse will monitor you for signs and symptoms of these reactions.<br><\/p>\n\n\n\n<p><strong>Tell your doctor, pharmacist or nurse immediately if<\/strong>&nbsp;you become pregnant while receiving BLINCYTO.&nbsp;The doctor will talk to you about precautions in connection with vaccinations of the child.<br><\/p>\n\n\n\n<p>Before each&nbsp;infusion&nbsp;of BLINCYTO, you will be given medicines that help to minimize a possible life-threatening complication called tumor lysis syndrome.&nbsp;The syndrome is due to chemical disorders in the blood, which are caused by the breakdown of dying cancer cells.&nbsp;You may also be given medicines to lower your fever.<br><\/p>\n\n\n\n<p>During treatment and especially during the very first days after starting treatment, you may experience a severe decrease in&nbsp;white blood cell count&nbsp;(&nbsp;neutropenia&nbsp;), severe decrease in&nbsp;white blood cell count&nbsp;and fever (febrile&nbsp;neutropenia&nbsp;), elevated liver levels or elevated levels of&nbsp;uric acid&nbsp;.&nbsp;Your doctor will regularly take blood samples to check the number of&nbsp;blood cells&nbsp;during treatment with BLINCYTO.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Children and young people<\/h2>\n\n\n\n<p>BLINCYTO should not be used by children under 1 year of age.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and BLINCYTO<\/h2>\n\n\n\n<p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<p>If you are pregnant, breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine.<br><\/p>\n\n\n\n<p><strong>Contraceptive<\/strong><\/p>\n\n\n\n<p>Women who may become pregnant should use an effective contraceptive during treatment and for at least 48 hours after the last treatment.&nbsp;Talk to your doctor or nurse about appropriate contraceptive methods.<br><\/p>\n\n\n\n<p><strong>Pregnancy<\/strong><\/p>\n\n\n\n<p>It is not known what effects BLINCYTO has on pregnant women, but given BLINCYTO&#8217;s mechanism of action, it could harm the unborn baby.&nbsp;Do not use BLINCYTO during pregnancy unless your doctor thinks it is the best medicine for you.<br><\/p>\n\n\n\n<p>If you become pregnant during treatment with BLINCYTO, tell your doctor or nurse.&nbsp;The doctor will talk to you about precautions in connection with vaccinations of the child.<br><\/p>\n\n\n\n<p><strong>Breast-feeding<\/strong><\/p>\n\n\n\n<p>You should not breast-feed during and for at least 48 hours after your last treatment.&nbsp;It is not known whether BLINCYTO is excreted in human milk, but a risk to the breast-fed baby cannot be ruled out.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Driving and using machines<\/h2>\n\n\n\n<p>You should not drive, use heavy machinery or engage in risky activities while receiving BLINCYTO.&nbsp;BLINCYTO can cause neurological problems, such as dizziness, seizures, confusion, coordination and balance disorders.<br><\/p>\n\n\n\n<p><strong>BLINCYTO contains&nbsp;sodium<\/strong><\/p>\n\n\n\n<p>This medicine contains less than 1 mmol (23 mg)&nbsp;sodium&nbsp;per&nbsp;dose&nbsp;, ie&nbsp;essentially &#8216;sodium-free&#8217;.&nbsp;is next to &#8220;sodium-free&#8221;.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">3. How to use BLINCYTO<\/h2>\n\n\n\n<p>Always use this medicine exactly as your doctor, pharmacist or nurse has told you.&nbsp;If you are not sure, talk to your doctor, pharmacist, or nurse.<br><\/p>\n\n\n\n<p><strong>How BLINCYTO is given<\/strong><\/p>\n\n\n\n<p>You will receive BLINCYTO via a vein (&nbsp;intravenously&nbsp;) for a&nbsp;continuous&nbsp;period of 4 weeks using an infusion pump (this is 1 treatment cycle).&nbsp;This is followed by a period of 2 weeks when you do not receive any&nbsp;infusion&nbsp;.&nbsp;You will have the infusion catheter inserted throughout the treatment cycle.<br><\/p>\n\n\n\n<p>Normally, 2 treatment cycles are given with BLINCYTO if you have&nbsp;recurrent&nbsp;or refractory&nbsp;acute&nbsp;lymphocytic&nbsp;leukemia&nbsp;, and 1 treatment cycle if you have&nbsp;acute lymphatic&nbsp;leukemia&nbsp;of the MRD type (minimal residual disease).&nbsp;If you respond well to this treatment, your doctor may decide to give you up to 3 additional treatment cycles.&nbsp;The number of treatment cycles and&nbsp;dose&nbsp;one you will receive depends on how well you tolerate and respond to BLINCYTO.&nbsp;The doctor will discuss with you how long treatment you should receive.&nbsp;Treatment may also be discontinued depending on how you tolerate BLINCYTO.<br><\/p>\n\n\n\n<p>If you have&nbsp;recurrent&nbsp;or refractory&nbsp;acute&nbsp;lymphocytic&nbsp;leukemia&nbsp;, it is recommended that you spend the first 9 days of treatment and the first 2 days of the second treatment cycle in a hospital under the supervision of a physician or nurse experienced in the use of anticancer drugs.<br><\/p>\n\n\n\n<p>If you have&nbsp;acute&nbsp;lymphatic&nbsp;leukemia&nbsp;of the type MRD (minimal residual disease), it is recommended that you spend the first 3 days of treatment and the first 2 days of subsequent treatment cycles, in a hospital under the supervision of a doctor or nurse experienced in the use of cancer drugs.<br><\/p>\n\n\n\n<p>If you have or have had neurological problems, it is recommended that you be treated in hospital for the first 14 days.&nbsp;The doctor will discuss with you if you can receive the continued treatment at home after the first hospital stay.&nbsp;The treatment may involve a nurse regularly changing the infusion bag.<br><\/p>\n\n\n\n<p>Your doctor will decide when to change your BLINCYTO infusion bag, which may vary from day to day every 4 days.&nbsp;The infusion rate may be faster or slower depending on how often the bag is changed.<br><\/p>\n\n\n\n<p><strong>The first treatment cycle<\/strong><\/p>\n\n\n\n<p>If you have&nbsp;recurrent&nbsp;or refractory&nbsp;acute&nbsp;lymphocytic&nbsp;leukemia&nbsp;and your body weight is greater than or equal to 45 kg, the recommended starting dose in the first treatment cycle is 9 micrograms per day for 1 week.&nbsp;The doctor may then decide to increase the&nbsp;dose&nbsp;one to 28 micrograms per day during treatment weeks 2, 3 and 4.<br><\/p>\n\n\n\n<p>If your body weight is less than 45 kg, the recommended starting dose in the first treatment cycle will be based on your weight and height.&nbsp;The doctor may then decide to increase the&nbsp;dose&nbsp;one in treatment weeks 2, 3 and 4.<br><\/p>\n\n\n\n<p>If you have&nbsp;acute&nbsp;lymphoblastic&nbsp;leukemia&nbsp;of the type MRD (minimal residual disease), your&nbsp;dose&nbsp;of BLINCYTO will be 28 micrograms per day during the first cycle.<br><\/p>\n\n\n\n<p><strong>Subsequent treatment cycles<\/strong><\/p>\n\n\n\n<p>If your doctor decides that you should receive additional BLINCYTO cycles and your body weight is 45 kg or more, your pump will be set to infuse a&nbsp;dose&nbsp;of 28 micrograms per day.<br><\/p>\n\n\n\n<p>If your doctor decides that you should receive additional BLINCYTO cycles and your body weight is less than 45 kg, your pump will be set to infuse a&nbsp;dose&nbsp;based on your weight and height.<br><\/p>\n\n\n\n<p><strong>Medicines that you receive before each BLINCYTO cycle<\/strong><\/p>\n\n\n\n<p>Before treatment with BLINCYTO you will be given other medicines (pre-medication) to minimize infusion&nbsp;reactions&nbsp;and other possible&nbsp;side effects&nbsp;.&nbsp;This may include treatment with&nbsp;cortisone&nbsp;(eg <a href=\"https:\/\/zeepedia.com\/medical\/medicines\/toflacort\/\">dexamethasone<\/a>).<br><\/p>\n\n\n\n<p><strong>Infusion catheter<\/strong><\/p>\n\n\n\n<p>If you have a&nbsp;catheter&nbsp;for&nbsp;infusion&nbsp;, it is very important that the area around the catheter is kept clean, otherwise there is a risk that you may get an&nbsp;infection&nbsp;.&nbsp;Your doctor or nurse will show you how to care for the catheter.<br><\/p>\n\n\n\n<p><strong>Infusion pump and intravenous tubes<\/strong><br><\/p>\n\n\n\n<p><strong>Do not adjust the pump settings<\/strong>&nbsp;, even if problems have occurred or if the pump is alarming.&nbsp;Any change in the pump settings can lead to a&nbsp;dose&nbsp;that is too high or too low.<br><\/p>\n\n\n\n<p>Contact a doctor or nurse immediately if:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>there is a problem with the pump or if the pump is alarming<\/li><li>the bag has been emptied before it is time for the next scheduled bag change<\/li><li>the infusion pump unexpectedly stops.&nbsp;Do not try to start the pump again.<\/li><\/ul>\n\n\n\n<p><br>The doctor or nurse will give you advice on how to take care of your daily tasks when you are connected to the pump.&nbsp;Contact your doctor or nurse if you have any questions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">4. Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause&nbsp;side effects, although not everybody gets them.&nbsp;Some of these&nbsp;side effects&nbsp;can be serious.<br><\/p>\n\n\n\n<p><strong>Tell<\/strong>&nbsp;your&nbsp;<strong>doctor immediately if<\/strong>&nbsp;you get any of the following or a combination of the following side effects:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>chills, chills, fever, rapid heartbeat, drop in blood pressure, aching muscles, feeling tired, coughing, difficulty breathing, confusion,&nbsp;redness&nbsp;, swelling or discharge in the affected area or at the infusion site &#8211; these may be signs of an&nbsp;infection<\/li><li>neurological symptoms: tremors (&nbsp;tremor&nbsp;), confusion, disorders of brain function (&nbsp;encephalopathy&nbsp;), communication difficulties (&nbsp;aphasia&nbsp;), seizures (convulsions)<\/li><li>fever, swelling, chills, decreased or elevated&nbsp;blood pressure&nbsp;and fluid in the lungs, which can become severe &#8211; these can be signs of a so-called cytokine release syndrome<\/li><li>if you suffer from severe and persistent stomach pain, with or without nausea and vomiting, as this may be a symptom of a serious and potentially fatal condition called&nbsp;pancreatitis&nbsp;(&nbsp;inflammation&nbsp;of the pancreas).<\/li><\/ul>\n\n\n\n<p>Treatment with BLINCYTO can cause a decrease in the levels of certain&nbsp;white blood cells&nbsp;with or without fever ((febrile)&nbsp;neutropenia&nbsp;or&nbsp;neutropenia&nbsp;) or can lead to elevated levels of&nbsp;potassium,&nbsp;uric acid,&nbsp;and&nbsp;phosphate&nbsp;in the blood as well as decreased calcium levels in the blood (tumor lysis syndrome).&nbsp;Your doctor will regularly take blood samples during treatment with BLINCYTO.<br><\/p>\n\n\n\n<p>Other&nbsp;side effects&nbsp;are:<\/p>\n\n\n\n<p><strong>Very common&nbsp;side effect&nbsp;is<\/strong>&nbsp;(can occur in more than 1 in 10):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>infection&nbsp;is in the blood caused by bacteria, fungi or&nbsp;viruses&nbsp;, or other types of&nbsp;infection&nbsp;er<\/li><li>decreased levels of certain&nbsp;white blood cells&nbsp;with or without fever ((febrile)&nbsp;neutropenia,&nbsp;leukopenia&nbsp;), decreased levels of&nbsp;red blood cells&nbsp;, decreased levels of&nbsp;platelets<\/li><li>fever, swelling, chills, decreased or elevated&nbsp;blood pressure&nbsp;and fluid in the lungs, which can be severe (cytokine release syndrome)<\/li><li>difficulty sleeping<\/li><li>headache, tremors (&nbsp;tremor&nbsp;)<\/li><li>rapid heartbeat (&nbsp;tachycardia&nbsp;)<\/li><li>low&nbsp;blood pressure<\/li><li>cough<\/li><li>nausea, diarrhea, vomiting, constipation, stomach pain<\/li><li>rash<\/li><li>back pain, pain in arms and \/ or legs<\/li><li>fever (&nbsp;pyrexia&nbsp;), swelling of the face, lips, mouth, tongue, or throat, which may cause difficulty swallowing or breathing (&nbsp;edema&nbsp;), chills<\/li><li>low levels of&nbsp;antibodies, called immunoglobulins, which help the immune system fight&nbsp;infections&nbsp;(reduced immunoglobulins)<\/li><li>elevated liver values \u200b\u200b(&nbsp;ALT,&nbsp;AST, GT)<\/li><li>reactions associated with&nbsp;infusion&nbsp;one, which may include wheezing when breathing, swelling, facial swelling, difficulty breathing, low&nbsp;blood pressure&nbsp;, high&nbsp;blood pressure&nbsp;.<br><\/li><\/ul>\n\n\n\n<p><strong>Common&nbsp;side effects&nbsp;are<\/strong>&nbsp;(may affect up to 1 in 10):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>serious&nbsp;infection, which can lead to organ failure,&nbsp;shock,&nbsp;or death (&nbsp;sepsis&nbsp;)<\/li><li>pneumonia&nbsp;(&nbsp;CAP&nbsp;)<\/li><li>elevated levels of&nbsp;white blood cells&nbsp;(&nbsp;leukocytosis&nbsp;), decreased levels of certain&nbsp;white blood cells&nbsp;(lymphopenia)<\/li><li>allergic reaction<\/li><li>complications after cancer treatment, which lead to elevated levels of&nbsp;potassium&nbsp;,&nbsp;uric acid&nbsp;and&nbsp;phosphate&nbsp;in the blood as well as to decreased levels of calcium in the blood (tumor lysis syndrome)<\/li><li>confusion, disorientation<\/li><li>disorders of brain function (&nbsp;encephalopathy&nbsp;), such as communication difficulties (&nbsp;aphasia&nbsp;), tingling in the skin (&nbsp;paresthesia&nbsp;), seizures, difficulty thinking clearly and reasoning, memory problems, difficulty coordinating body movement (&nbsp;ataxia)<\/li><li>drowsiness (&nbsp;somnolence&nbsp;), numbness, dizziness<\/li><li>nerve problems affecting the head and neck, such as visual disturbances, drooping eyelids and\/or drooping muscles on one side of the face, hearing problems, or difficulty swallowing (cranial nerve disorder)<\/li><li>wheezing or breathing difficulties (&nbsp;dyspnoea&nbsp;), shortness of breath (respiratory failure)<\/li><li>high&nbsp;blood pressure&nbsp;(&nbsp;hypertension&nbsp;)<\/li><li>hot flashes<\/li><li>slemhosta<\/li><li>elevated&nbsp;bilirubin&nbsp;in the blood<\/li><li>skeletal pain<\/li><li>chest pain or other pain<\/li><li>high levels of certain&nbsp;enzymes, including blood enzymes<\/li><li>weight gain.<\/li><\/ul>\n\n\n\n<p><strong>Less common&nbsp;side effects&nbsp;are<\/strong>&nbsp;(may affect up to 1 in 100):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>excessive activation of&nbsp;white blood cells&nbsp;associated with&nbsp;inflammation(haemophagocytic histiocytosis)<\/li><li>swollen&nbsp;lymph nodes&nbsp;(&nbsp;lymphadenopathy&nbsp;)<\/li><li>fever, swelling, chills, decreased or elevated&nbsp;blood pressure&nbsp;and fluid in the lungs, which can be severe and lead to death (cytokine storm)<\/li><li>a condition that causes fluid from small blood vessels to leak into the body (capillary leakage syndrome).<\/li><li>speech difficulties<\/li><li>nerve problems affecting the head and neck, such as visual disturbances, drooping eyelids and \/ or drooping muscles on one side of the face, hearing problems or difficulty swallowing (cranial nerve disorder).<\/li><\/ul>\n\n\n\n<p>Side effects&nbsp;that occurred more often in adolescents and children are:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>decreased number of&nbsp;red blood cells&nbsp;(&nbsp;anemia&nbsp;), decreased number of&nbsp;platelets&nbsp;(&nbsp;thrombocytopenia&nbsp;), decreased number of certain&nbsp;white blood cells&nbsp;(&nbsp;leukopenia&nbsp;)<\/li><li>fever (&nbsp;pyrexia&nbsp;)<\/li><li>reactions associated with&nbsp;infusion&nbsp;one, which may include facial swelling, low&nbsp;blood pressure, high&nbsp;blood pressure&nbsp;(infusion-related reaction)<\/li><li>weight gain<\/li><li>high&nbsp;blood pressure&nbsp;(&nbsp;hypertension&nbsp;)<\/li><\/ul>\n\n\n\n<p><em>Reporting of side effects<\/em><\/p>\n\n\n\n<p>If you get any side effects, talk to your doctor, pharmacist, or nurse.&nbsp;This includes any possible side effects not listed in this leaflet.&nbsp;You can also report side effects directly to the Medical Products Agency,&nbsp;www.lakemedelsverket.se.&nbsp;By reporting side effects, you can help increase drug safety information.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">5. How to store BLINCYTO<\/h2>\n\n\n\n<p>Keep this medicine out of the sight and reach of children.<br><\/p>\n\n\n\n<p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP.&nbsp;The expiration date is the last day of the specified month.<br><\/p>\n\n\n\n<p><strong>Unopened vials:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Store and transport cold (2 \u00b0 C &#8211; 8 \u00b0 C).<\/li><li>Do not freeze.<\/li><li>Store in the original package.&nbsp;Sensitive to light.<\/li><\/ul>\n\n\n\n<p><strong>Ready-made solution (BLINCYTO solution):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Reconstituted solution stored cold must be used within 24 hours.&nbsp;The vials can alternatively be stored at room temperature (up to 27 \u00b0 C) for up to 4 hours.<\/li><\/ul>\n\n\n\n<p><strong>Diluted solution (reconstituted&nbsp;infusion bag&nbsp;):<\/strong><\/p>\n\n\n\n<p>If your&nbsp;infusion bag&nbsp;is changed at home:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Infusion bags with BLINCYTO solution for&nbsp;infusion&nbsp;come in special packages that contain &#8220;cooling lamps&#8221;.<ul><li>Do not open the package.<\/li><li>Store the package at room temperature (up to 27 \u00b0 C).<\/li><li>The packaging must not be stored in the refrigerator or freezer.<\/li><\/ul><\/li><li>The nurse opens the package and the infusion bag is then stored in the refrigerator until&nbsp;infusion&nbsp;one.<\/li><li>Once stored in the refrigerator, the infusion bags must be used within 10 days of preparation.<\/li><li>Once the solution has reached room temperature (up to 27 \u00b0 C), it should be infused within 96 hours.<\/li><\/ul>\n\n\n\n<p>Medicines should not be disposed of via wastewater or household waste.&nbsp;Ask your pharmacist how to dispose of medicines no longer required.&nbsp;These measures will help to protect the environment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">6. Contents of the packaging and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Content declaration<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>The active substance is blinatumomab.&nbsp;One&nbsp;vial&nbsp;of powder contains 38.5 micrograms of blinatumomab.&nbsp;Reconstitution with water for injections gives a final blinatumomab concentration of 12.5 micrograms\/ml.<\/li><li>The other ingredients in the powder are citric acid monohydrate (E330), trehalose dihydrate, lysine hydrochloride, polysorbate 80 and sodium hydroxide.<\/li><li>The solution (stabilizer) contains citric acid monohydrate (E330), lysine hydrochloride, polysorbate 80, sodium hydroxide and water for injections.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What the medicine looks like and the contents of the pack<\/h2>\n\n\n\n<p>BLINCYTO is a powder for concentrate and a solution for&nbsp;infusion&nbsp;solution.<\/p>\n\n\n\n<p>Each package BLINCYTO contains:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>1 glass bottle containing white to off-white powder.<\/li><li>1 glass bottle containing a colorless to the slightly yellowish clear solution.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorization Holder and Manufacturer<\/h2>\n\n\n\n<p>Amgen Europe BV<\/p>\n\n\n\n<p>Minervum 7061<\/p>\n\n\n\n<p>4817 ZK Breda<\/p>\n\n\n\n<p>Netherlands<br><\/p>\n\n\n\n<p>Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The active substance in BLINCYTO is blinatumomab. It belongs to a group of drugs called cytostatic \/ cytotoxic drugs that target cancer cells.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2202,2200],"tags":[8641,8643,8646,8649,8645,8650,8644,8648,8642,8647],"class_list":["post-6152","post","type-post","status-publish","format-standard","hentry","category-b","category-medicines","tag-blinatumomab","tag-blinatumomab-side-effects","tag-blincyto","tag-blincyto-side-effects","tag-side-effects-of-blinatumomab","tag-side-effects-of-blincyto","tag-what-blinatumomab-is-used-for","tag-what-blincyto-is-used-for","tag-what-is-blinatumomab","tag-what-is-blincyto"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/6152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=6152"}],"version-history":[{"count":5,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/6152\/revisions"}],"predecessor-version":[{"id":11922,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/6152\/revisions\/11922"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=6152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=6152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=6152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}